The Gross Margin of Prelude Therapeutics Incorporated (PRLD) is
7775.20%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2025-12-31 |
7775.20%
|
| Ticker |
Name |
Value |
|
AMGN
|
Amgen Inc
|
70.78%
|
|
BCAB
|
Bioatla Inc
|
7775.20%
|
|
GILD
|
Gilead Sciences, Inc.
|
78.84%
|
|
IGMS
|
IGM Biosciences LLC
|
7775.20%
|
|
ABBV
|
AbbVie Inc.
|
71.62%
|
|
ADCT
|
Adc Therapeutics Ltd
|
92.87%
|
|
CGEM
|
Cullinan Therapeutics, Inc.
|
7775.20%
|
|
KURA
|
Kura Oncology, Inc.
|
99.92%
|
|
DCPH
|
Deciphera Pharmaceuticals Inc
|
97.72%
|
|
GBT
|
Global Blood Therapeutics Inc
|
98.30%
|
|
KYMR
|
Kymera Therapeutics, Inc.
|
7775.20%
|
|
950220.KQ
|
Neoimmunetech Inc
|
7775.20%
|
|
FGEN
|
FibroGen Inc
|
47.47%
|
|
INO
|
Inovio Pharmaceuticals Inc
|
60.13%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
86.56%
|
|
SWTX
|
SpringWorks Therapeutics, Inc.
|
93.45%
|
|
ALXO
|
ALX Oncology Holdings Inc
|
9.32%
|
|
GBIO
|
Generation Bio Co
|
7775.20%
|
|
MRNA
|
Moderna, Inc.
|
70.32%
|
|
OLMA
|
Olema Pharmaceuticals, Inc.
|
7775.20%
|
|
RCUS
|
Arcus Biosciences, Inc.
|
7775.20%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
13.28%
|
|
AMTI
|
Applied Molecular Transport Inc.
|
7775.20%
|
|
MYOV
|
Myovant Sciences Ltd
|
77.68%
|
|
NRIX
|
Nurix Therapeutics, Inc.
|
7775.20%
|
|
RUBY
|
Rubius Therapeutics Inc
|
7775.20%
|
|
IMCR
|
Immunocore Holdings PLC
|
98.73%
|
|
MCRB
|
Seres Therapeutics, Inc.
|
7775.20%
|
|
PMVP
|
Pmv Pharmaceuticals, Inc
|
7775.20%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
86.24%
|
|
950200.KQ
|
Psomagen Inc
|
24.48%
|
|
ALVR
|
Allovir Inc
|
7775.20%
|
|
DMTK
|
DermTech Inc
|
1.80%
|
|
LGND
|
Ligand Pharmaceuticals Incorporated
|
74.78%
|
|
VIE
|
Viela Bio Inc
|
82.49%
|